Y Wang1, P Liu1. 1. Department of Infectious Diseases, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning Province, China.
Abstract
WHAT IS KNOWN AND THE OBJECTIVE: Sofosbuvir (SOF) and daclatasvir (DCV) have revolutionized the treatment of hepatitis C virus and now represent the preferred therapy for this disease. Limited data are available on the dermatological side effects resulting from co-administration of SOF and DCV. CASE DESCRIPTION: We report a case of an erythema multiforme drug eruption associated with erythrodermic psoriasis induced by SOF and DCV. After ceasing treatment, the skin condition significantly improved. WHAT IS NEW AND CONCLUSION: We should pay attention to adverse skin reactions resulting from SOF and DCV, especially if the patient has a pre-existing dermatosis.
WHAT IS KNOWN AND THE OBJECTIVE: Sofosbuvir (SOF) and daclatasvir (DCV) have revolutionized the treatment of hepatitis C virus and now represent the preferred therapy for this disease. Limited data are available on the dermatological side effects resulting from co-administration of SOF and DCV. CASE DESCRIPTION: We report a case of an erythema multiforme drug eruption associated with erythrodermic psoriasis induced by SOF and DCV. After ceasing treatment, the skin condition significantly improved. WHAT IS NEW AND CONCLUSION: We should pay attention to adverse skin reactions resulting from SOF and DCV, especially if the patient has a pre-existing dermatosis.